<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230801059003N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-16</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Efficacy of melatonin in fetal pulmonary artery doppler index and a role of this parameters in prevention of neonatal respiratory distress syndrome in preterm neonates with maternal abnormal implantation placenta</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of melatonin in fetal pulmonary artery doppler index and a role of this parameters in prevention of neonatal respiratory distress syndrome in preterm neonates with maternal abnormal implantation placenta</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71797</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Blocked randomization method will be used for randomly assigning the intervention and control groups. The number of blocks will be four and will be in the form of code a and b.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Preterm neonates. Condition 2: Infant respiratory distress.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 19 to 45-year-old singleton pregnant women without fetal anomalies with a gestational age of 32-34 weeks with placental disorders (ecreta, increta, percreta, previa) without any other underlying disease will be included in the study. Melatonin tablets of 10 mg (2 tablets of 5 mg) are given daily before going to bed for a period of 2 weeks. The sample number is 64 people, of which 32 people are in this group (melatonin consumption group). Doppler examination of the pulmonary artery by measuring AT/ET in ultrasound is done before the start of melatonin treatment once and again the day before delivery, and the baby is evaluated after birth, and the results of the Doppler indices are compared with the condition of the baby in two groups. Intervention 2: Control group: Control group: 19-45-year-old singleton pregnant women without fetal anomalies with a gestational age of 32-34 weeks with placental disorders (ecreta, increta, precreta, previa) without any other underlying disease will be included in the study. This group will not be treated with melatonin tablets, and there are 32 people in this group (group without melatonin). Pulmonary artery doppler examination by measuring ET (ejection time) AT (acceleration time) AT/ET is performed in ultrasound once a day before delivery and the baby is evaluated after birth and the results of pulmonary artery doppler indices are compared with the condition of the baby after birth. will be.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Intellectual Property/Confidentiality Issues/Ethical Concerns</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bahar Farshidfar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Keshavarz Blvd., corner of Qods</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1416633591</zip>
        <telephone>0098218895586</telephone>
        <email>farshidfarbahar@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bahar Farshidfar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Keshavarz Blvd., corner of Qods</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1416633591</zip>
        <telephone>0098218895586</telephone>
        <email>farshidfarbahar@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Singleton pregnant women with gestational age of 32-34 weeks with placental disorders (acreta, increta, percreta, previa)</inclusion_criteria>
      <agemin>19 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Fetal anomaly
Mother's underlying disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O60.3</hc_code>
      <hc_code>P22.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Preterm delivery by: caesarean section, without spontaneous labour</hc_keyword>
      <hc_keyword>Other respiratory distress of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 19 to 45-year-old singleton pregnant women without fetal anomalies with a gestational age of 32-34 weeks with placental disorders (ecreta, increta, percreta, previa) without any other underlying disease will be included in the study. Melatonin tablets of 10 mg (2 tablets of 5 mg) are given daily before going to bed for a period of 2 weeks. The sample number is 64 people, of which 32 people are in this group (melatonin consumption group). Doppler examination of the pulmonary artery by measuring AT/ET in ultrasound is done before the start of melatonin treatment once and again the day before delivery, and the baby is evaluated after birth, and the results of the Doppler indices are compared with the condition of the baby in two groups.</i_keyword>
      <i_keyword>Control group: Control group: 19-45-year-old singleton pregnant women without fetal anomalies with a gestational age of 32-34 weeks with placental disorders (ecreta, increta, precreta, previa) without any other underlying disease will be included in the study. This group will not be treated with melatonin tablets, and there are 32 people in this group (group without melatonin). Pulmonary artery doppler examination by measuring ET (ejection time) AT (acceleration time) AT/ET is performed in ultrasound once a day before delivery and the baby is evaluated after birth and the results of pulmonary artery doppler indices are compared with the condition of the baby after birth. will be</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pulmonary artery Doppler of the fetus. Timepoint: 2 weeks. Method of measurement: Philips ultrasound.</prim_outcome>
      <prim_outcome>Apgar minutes 1 and 5. Timepoint: Day 1, birthday, minutes 1 and 5. Method of measurement: clinical.</prim_outcome>
      <prim_outcome>The degree of respiratory distress of the infant. Timepoint: day 1 birthday. Method of measurement: clinical.</prim_outcome>
      <prim_outcome>Middle cerebral artery Doppler. Timepoint: 2 weeks. Method of measurement: Philips ultrasound.</prim_outcome>
      <prim_outcome>Doppler of the umbilical artery. Timepoint: 2 weeks. Method of measurement: Philips ultrasound.</prim_outcome>
      <prim_outcome>Uterine artery doppler. Timepoint: 2 weeks. Method of measurement: Philips ultrasound.</prim_outcome>
      <prim_outcome>Neonatal resuscitation. Timepoint: First day after birth. Method of measurement: clinical.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-19</approval_date>
        <contact_name>Research Ethics Committees of Imam Khomeini Hospital Complex- Tehran University of Medical Sciences</contact_name>
        <contact_address>Tehran University of Medical Sciences Headquarters, Qods Corner, Keshavarz Blvd. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
